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Abstract 
Gastrointestinal stromal tumors (GISTs) have been recognized as a biologically distinctive type of tumor, different 
from smooth muscle and neural tumors of the gastrointestinal tract. The identification of genetic aberrations in 
proto-oncogenes that drive the growth of GISTs is critical for improving the efficacy of cancer therapy by match-
ing targeted drugs to specific mutations. Research into the oncogenic mechanisms of GISTs has found that these 
tumors frequently contain activating gene mutations in either platelet-derived growth factor receptor A (PDGFRA) or a 
receptor tyrosine protein associated with a mast cell growth factor receptor encoded by the KIT gene. Mutant cancer 
subpopulations have the potential to disrupt durable patient responses to molecularly targeted therapy for GISTs, yet 
the prevalence and size of subpopulations remain largely unexplored. Detection of the cancer subpopulations that 
harbor low-frequency mutant alleles of target proto-oncogenes through the use of molecular genetic methods, such 
as polymerase chain reaction (PCR) target amplification technology, is hampered by the high abundance of wild-
type alleles, which limit the sensitivity of detection of these minor mutant alleles. This is especially true in the case of 
mutant tumor DNA derived “driver” and “drug-resistant” alleles that are present in the circulating cell-free tumor DNA 
(cfDNA) in the peripheral blood circulation of GIST patients. So-called “liquid biopsy” allows for the dynamic monitor-
ing of the patients’ tumor status during treatment using minimally invasive sampling. New methodologies, such as 
a technology that employs a xenonucleic acid (XNA) clamping probe to block the PCR amplification of wild-type 
templates, have allowed improved molecular detection of these low-frequency alleles both in tissue biopsy samples 
and in cfDNA. These new methodologies could be widely applied for minimally invasive molecular testing in the 
therapeutic management of GISTs.
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Background
Gastrointestinal stromal tumors (GISTs) are the most 
common mesenchymal tumors of the gastrointestinal 
tract, accounting for approximately 20% of all sarcomas 
[1, 2]. Sarcomas are a rare type of cancer that can occur 
in the bones, muscles, nerves, blood vessels, connective 
tissue, fat, and cartilage. The neoplastic GIST cell appears 
to arise from a common precursor cell, which gives rise 
to the interstitial cells of Cajal in the normal myenteric 
plexus [3]. GISTs are characterized by mutations in a 
receptor tyrosine protein (encoded by the KIT gene) 
associated with a mast cell growth factor receptor or in 
the gene encoding platelet-derived growth factor recep-
tor A (PDGFRA). These genetic aberrations lead to con-
stitutive activation of these growth factor receptors and 
concomitant abnormal cellular proliferation, which leads 
to the development of GIST.
Early detection of these genetic alterations is important 
for diagnosis and therapy and for monitoring the pro-
gression of GIST. This article provides an overview of the 
Open Access
Chinese Journal of Cancer
*Correspondence:  mpowell@diacarta.com 
2 DiaCarta Inc., 2600 Hilltop Drive, Richmond, CA 94806, USA
Full list of author information is available at the end of the article
Page 2 of 8Yan et al. Chin J Cancer  (2016) 35:68 
current status of targeted molecular therapies for GISTs 
and the current state-of-the-art of high-sensitivity molec-
ular genetic tests that are able to detect low-frequency 
tumor-derived mutations in cancer patients employing 
minimally invasive sampling, i.e., “liquid biopsy”.
Kinase mutations in GISTs
The biology of GISTs has been widely investigated at the 
genomic level. Mutations in KIT or the receptor tyrosine 
kinase PDGFRA are the hallmarks of molecular diagnosis 
of GIST. KIT and PDGFRA are mutated in approximately 
85% and 5%, respectively, of GISTs. Mutations are also 
rarely (<1%) found in the serine-threonine protein kinase 
BRAF (Fig. 1) [4].
Approximately 80% of GISTs have an oncogenic muta-
tion in the tyrosine kinase KIT [5–7]. Most of these 
mutations affect the juxtamembrane domain encoded 
by KIT exon 11, allowing spontaneous (ligand-inde-
pendent) receptor dimerization and kinase activation. 
However, mutations also occur in exons 9, 13, and 17, 
and these mutations may support constitutive KIT sign-
aling through other mechanisms. A subset (5%–7%) of 
GISTs have an activating mutation in the KIT-homol-
ogous tyrosine kinase PDGFRA [8, 9]. Many of these 
PDGFRA-mutant GISTs have an epithelioid morphology 
and express little or no KIT; however, such features are 
not unique to these tumors, and mutation status can be 
determined only through molecular analysis. Approxi-
mately 10%–15% of GISTs are negative for KIT and PDG-
FRA gene mutations; these tumors are often referred to 
as wild-type GISTs (Fig. 2) [10, 11].
Mutant and wild-type GISTs show marked differ-
ences in imatinib response. The response rates were 
approximately 80% in GIST patients with KIT exon 11 
mutants, 40% in those with KIT exon 9 mutants, and 14% 
in wild-type GIST patients [12]. GIST patients with PDG-
FRA mutations showed mild sensitivity to imatinib (66%), 
with the exception of those with the exon 18 point muta-
tion D842V, who were totally resistant to imatinib [12]. 
In addition to the importance of GIST mutational status 
in predicting imatinib sensitivity, as described above, 
the acquisition of secondary mutations in either KIT or 
PDGFRA represents the most frequent mechanism of 
imatinib resistance in GISTs. Advances in whole genome 
analysis technology has shown that GISTs with wild-type 
KIT/PDGFRA should be considered more appropriately 
as a heterogeneous family of distinct disease entities, 
with different biological and clinical features [13].
BRAF belongs to the RAF family of serine-threonine 
protein kinases. These kinases participate in the RAS-
RAF-ERK pathway, which regulates cell cycle through 
activation of the mitogen-activated protein kinase 
(MAPK) pathway. BRAF mutations have been detected in 
GIST patients with wild-type KIT/PDGFRA. In a recent 
study, BRAF exon 15 V600E mutation was detected in 
13% (9 of 70) of patients with wild-type KIT/PDGFRA 
GISTs [14]. In naïve GIST patients carrying activating 
mutations in KIT or PDGFRA, a concomitant activat-
ing mutation in BRAF gene (in approximately 2% of the 
patients) was found to be consistent with resistance [15]. 
In this study, in vitro experiments showed that imatinib 
was able to switch off the mutated activated receptor KIT 
but not the downstream signaling triggered by the BRAF 
mutation [15].
The most common primary mutations in KIT affect the 
juxtamembrane domain encoded by exon 11. Two-thirds 
of GISTs harbor KIT mutations in exon 11, which dis-
rupt the normal juxtamembrane secondary structure that 
prevents the kinase activation loop from swinging into 
active conformation [16]. These mutations include in-
frame deletions, insertions, and substitutions, as well as 
combinations of these. The deletions are associated with 
shorter progression-free and overall survival in compari-
son to other exon 11 mutations. In particular, deletions 
involving codon 557 and/or codon 558 are associated 
with malignant behavior [17].
Aside from exon 11 mutations, 7%–10% of GISTs have a 
KIT mutation in an extracellular domain that is encoded 
by exon 9. These mutations are thought to mimic the 
conformational change that the KIT receptor undergoes 
when stem cell factor (SCF) is bound. Importantly, the 
kinase domain in exon 9-mutant KIT is essentially the 
same as in wild-type KIT and has an effect on inhibitor 
sensitivity. Also important is that these mutations occur 
in tumors that arise in the intestines but are rarely seen in 
the stomach. KIT mutations in the activation loop (which 
Fig. 1 Molecular subsets of gastrointestinal stromal tumors (GISTs). 
Gene that encodes a receptor tyrosine protein associated with a 
mast cell growth factor receptor (KIT); platelet-derived growth factor 
receptor A (PDGFRA); gene that encodes an enzyme belonging to the 
RAF family of serine-threonine protein kinases participating in the 
RAS-RAF-ERK pathway (BRAF); wild-type (WT) normal gene sequence 
that does not contain any somatic mutations
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is encoded by exon 17) of the kinase are uncommon 
and stabilize the active conformation. KIT mutations 
in the ATP-binding region encoded by exon 13 (such as 
K642E) are also uncommon. Secondary mutations are 
concentrated in two regions of the KIT kinase domain. 
One target is the ATP-binding pocket, encoded by exons 
13 and 14, the part of the protein that directly interferes 
with drug binding. The other target is the activation loop, 
where mutations can stabilize KIT in the active confor-
mation and thereby hinder drug interaction. By contrast, 
the secondary ATP-binding pocket mutations do not 
cause intrinsic kinase activation.
Crystal structure analysis of KIT has shown that in the 
absence of the ligand, the juxtamembrane domain folds 
back into the active site of the kinase. Disruption of the 
juxtamembrane domain by mutation is believed to lead 
to activation of the kinase by removal of this auto-inhibi-
tion. The prognostic significance of mutations in the KIT 
and PDGFRA genes has been examined in GISTs in the 
pre-imatinib era, and tumors with a KIT exon 11 muta-
tion are associated with a worse outcome than tumors 
with other KIT or PDGFRA mutant isoforms or with no 
detectable mutation [18–22]. Conversely, KIT exon 11 
mutations have been found in mitotically inactive GISTs 
of 1 cm or smaller, suggesting that oncogenic KIT activ-
ity contributes to early tumor growth [23, 24]. GISTs 
with a KIT exon 9 mutation arise predominantly in the 
small intestine and colon and appear to be clinically more 
aggressive than tumors with KIT exon 11 mutations [25, 
26]. In contrast, tumors with PDGFRA mutations are less 
aggressive than those with KIT mutations [27, 28].
Current targeted therapies for GISTs
The golden standard GIST therapy is the tyrosine kinase 
inhibitor (TKI) imatinib, which offers a good and sta-
ble response for approximately 18–36 months; however, 
development of resistance is very common. The detection 
of somatic mutations from cancer genome sequences is 
the key to understanding the genetic basis of disease pro-
gression, patient survival, therapy response, and toxic-
ity. The DNA of the tumor serves as the primary source 
of information, which over the years has led to a more 
detailed characterization of the biological profile of GIST.
For GISTs, the main objective of treatment is complete 
resection. As discussed above, TKIs such as imatinib 
or sunitinib (Fig.  3) are used for neoadjuvant, adjuvant, 
Fig. 2 Schematic structures of PDGFRA and KIT. a Primary oncogenic mutation in PDGFRA. b Distribution of primary and secondary mutations in KIT. 
EC extracellular domain, M membrane, JM juxtamembrane domain, TK I tyrosine kinase domain I, KI kinase insert, TK II tyrosine kinase domain II
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or palliative treatment. Sunitinib malate is an oxindole 
molecule designed to interact selectively with the intra-
cellular ATP-binding sites of tyrosine kinase vascular 
endothelial growth factor receptors 1–3 (VEGFR1–3), 
platelet-derived growth factor receptors (PDGFRs), stem 
cell growth factor receptor (KIT), fms-related tyrosine 
kinase 3 (FLT3), and colony-stimulating factor 1 receptor 
(CSF1R).
Receptor inhibition has multiple effects on cellular 
processes, including tumor cell survival, endothelial cell 
growth and migration, vascular permeability, pericyte 
recruitment, and lymphangiogenesis. The final antitu-
mor effects may be classified as follows: direct cytotoxic 
effects on tumor cells by induction of cell death, anti-
angiogenic effects leading to growth delay and/or tumor 
regression by cytostatic inhibition of new blood-vessel 
formation, vascular disruption by inhibition of existing 
VEGF/VEGFR-dependent tumor blood vessels leading 
to central tumor cell necrosis, and cavitation that may or 
may not be associated with tumor regression. Responses 
to imatinib can be achieved; however, treatment is 
not curative unless complete resection is possible. In 
advanced GISTs, a partial remission can be attained in 
50% of patients treated with imatinib, and there are sin-
gle cases of complete responses. However, most patients 
receiving imatinib experience disease progression [29–
34]. Patients receiving imatinib who progress only tran-
siently respond to sunitinib [6, 35, 36].
For patients with GISTs, the response to therapy is 
evaluated by diagnostic imaging, which displays limited 
sensitivity and specificity. Computed tomography (CT) 
constitutes the golden standard of imaging for GIST 
[37, 38]. However, sensitivity of CT in detecting GISTs 
is insufficient. Currently, there is no biomarker available 
for detecting success or failure of therapy in GISTs. Acti-
vating mutations in KIT or PDGFRA can be found in at 
least 85% of all GISTs and constitute the transforming 
event in the pathogenesis of GIST tumors. In addition, 
mutated genomic DNA fragments are highly specific for 
the tumor. High sensitivity methods for the detection of 
these mutations are needed. Currently, there is limited 
clinical sensitivity of Sanger dideoxy sequencing; at least 
~20% of the DNA derived from the tumors needs to be 
detectable mutants, meaning that GISTs harboring muta-
tions below this threshold will go undetected.
Mutation detection of circulating cell‑free tumor 
DNA (cfDNA) for diagnosis and cfDNA‑targeted 
therapy for cancer
Circulating cfDNA can be detected in healthy individu-
als but is increased in patients with tumors [39–43]. 
Proposed models for tumor DNA release into the blood 
include DNA release by tumor cells that undergo apop-
tosis or necrosis and extravasation of tumor cells into the 
blood, where cells undergo lysis.
It has been shown that the levels of long interspersed 
nucleotide elements 1 (LINE1) DNA in plasma sam-
ples associate with tumor progression in different can-
cer entities [44–47]; however, LINE1 sequences are not 
tumor-specific. It has also been shown that growth factor 
Fig. 3 Chemical structures of the tyrosine kinase inhibitors (TKIs) imatinib [Gleevec, approved by the Food and Drug Administration (FDA) of the 
United States in 2002 for the treatment of advanced GIST patients and marketed by Novartis] and sunitinib (Sutent, approved by the FDA in 2006 for 
the treatment of patients with imatinib-resistant GIST and marketed by Pfizer)
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mutations can be recovered in cfDNA in serum sam-
ples of patients with non-small cell lung cancer [48], and 
detection of circulating mutant tumor suppressors ade-
nomatous polyposis coli (APC) and p53, or KRAS DNA 
was shown to associate with progression-free survival in 
patients with colorectal cancer [49].
cfDNA in GISTs
Understanding the genetic landscape of GISTs is impor-
tant for selection of the most appropriate medical treat-
ment. A sensitive, reliable biomarker for detection and 
quantitation of disease activity would be a highly valu-
able tool for the management of GIST. Traditionally, 
DNA extracted from formalin-fixed, paraffin-embedded 
specimens has been used for genetic analysis. However, 
a recent study showed that tumor-specific mutations in 
KIT or PDGFRA can be detected and quantified in cir-
culating cfDNA in plasma samples from patients with 
GIST. This technique is known as “liquid biopsy” [50]. A 
target amplification methodology known as quantitative 
ligation polymerase chain reaction (PCR) was used, and 
the cfDNA levels were associated with the clinical course 
of the GIST lesions as measured by diagnostic imaging. 
Thus, tumor-specific cfDNA in plasma can be used as a 
highly specific biomarker in patients with GIST and can 
also be used to predict treatment responses and relapse, 
allowing for earlier changes in treatment.
A sponsored clinical trial is currently being conducted in 
Italy (ClinicalTrials.gov identifier: NCT0244398; https://
clinicaltrials.gov/ct2/show/NCT02443948) to establish 
an association between the change in cfDNA and disease 
state of GISTs. Another recent study using next-generation 
sequencing (NGS) successfully detected secondary KIT 
mutations in circulating cfDNA from the peripheral blood 
of GIST patients undergoing imatinib therapy [51].
QClamp™ mutation assays using cfDNA
For the high-sensitivity detection of low-frequency muta-
tions in tumor-derived cfDNA, a technology has been 
developed that uses a polymerase chain reaction xeno-
nucleic acid clamping approach (XNA-PCR; QClamp™). 
This novel technology has been developed for the detec-
tion of low-frequency mutations in tumor-derived DNA 
[52] and the early detection of mutations in cfDNA from 
cancer patients [53] and from stool-derived DNA in colo-
rectal cancer patients [54]. This technology allows for 
the selective primer-mediated DNA polymerase-based 
amplification of only mutant template in tumor-derived 
DNA because the wild-type templates are blocked by the 
highly specific XNA probes used during PCR (Fig. 4).
Mutations in growth factor receptor pathways can guide 
a physician in choosing the appropriate precision ther-
apy for a particular cancer. QClamp™ can detect muta-
tions in tumor-derived cfDNA from plasma samples. 
The QClamp™ method is highly sensitive and can detect 
mutations at a level below 0.1% (1 mutant copy in 1000 
wild-type copies). For example, KIT mutations in exon 17, 
particularly at codon 816, lead to activation of the kinase 
in GISTs. Figure 5 shows the real-time PCR profile for the 
high-sensitivity detection of this mutation at <0.1%.
The QClamp™ XNA-PCR technology has also been used 
to detect low-frequency mutations in breast cancer patient 
samples [55] and fine needle aspiration (FNA) biopsy 
samples [56], which further demonstrates the practical 
Fig. 4 QClamp™ xenonucleic acid (XNA) probe hybridizes to wild-type DNA (WT-DNA) templates and prevents WT-DNA from being amplified, 
while melting off from the mutant DNA template so that only mutant DNA is amplified
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clinical use of the technology for detection of low-fre-
quency mutant tumor alleles in tumor biopsy samples.
Conclusions
The prognosis for GIST patients has changed enormously 
over the past few decades. In particular, imatinib has 
radically changed life expectancy of patients with GIST, 
a group of patients previously considered to be largely 
untreatable. For those with disease refractory to imatinib, 
as well as the majority who develop resistance to 
imatinib, other TKIs, such as sunitinib and regorafenib, 
are available. As more drug options become available, 
mutation testing by pathologists will become more com-
mon to select the best drugs for treatment depending on 
Fig. 5 QClamp™ assay for KIT exon 17 D816V/Y/H mutation detection performed with template DNA containing D816V mutations at the allelic 
frequencies shown. a Real-time polymerase chain reaction (PCR) profiles KIT D816V amplification plots. b Melting curves for PCR amplicons clearly 
demonstrate detection sensitivity of >99.9% (i.e., 1 mutant allele in 1000 wild-type alleles)
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the characteristics of the tumor, whether the treatment is 
for primary tumors or not, and whether there are metas-
tases that are present at diagnosis or that develop during 
treatment.
The high sensitivity of QClamp™ technology and 
its ability to be performed using widely available real-
time PCR instrumentation platforms such as ABI 
7500, Roche LC480, and Rotor-Gene Q make it highly 
attractive for clinical applications where a rapid “sam-
ple-to-answer” result is needed for precise medical 
applications. It is expected that the QClamp™ technol-
ogy will find wide application in the minimally invasive 
detection of tumor-specific mutations to aid in the early 
diagnosis of GISTs and the development of targeted 
therapies.
Authors’ contributions
MJP drafted the manuscript, genetic analysis was performed under supervi-
sion of MJP, AZ and WY revised the draft. All authors read and approved the 
final manuscript.
Author details
1 Robotics Research Institute, School of Mechanical Engineering, Shanghai Jiao 
Tong University, Shanghai 200240, P.R. China. 2 DiaCarta Inc., 2600 Hilltop Drive, 
Richmond, CA 94806, USA. 
Competing interests
The authors declare that they have no competing interests.
Received: 17 November 2015   Accepted: 26 May 2016
References
 1. Zhang W. TCGA divides gastric cancers into four molecular sub-
types: implications for individualized therapeutics. Chin J Cancer. 
2014;33:469–70.
 2. Chen W, Zheng R, Zeng H, Zhang S. The updated incidences and mortali-
ties of major cancers in China, 2011. Chin J Cancer. 2015;34:53.
 3. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the 
gastrointestinal tract. Histol Histopathol. 2000;15:1293–301.
 4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. 
Gain of function mutations of c-kit in human gastrointestinal stromal 
tumors. Science. 1998;279:577–80.
 5. Maki R, Keedy V. Molecular profiling of gastrointestinal stromal tumor 
(GIST). My Cancer Genome. 2015. https://www.mycancergenome.org/
content/disease/gist/. Accessed 16 Mar 2016.
 6. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal 
tumors. J Clin Oncol. 2004;22:3813–25.
 7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on mor-
phology, molecular pathology, prognosis, and differential diagnosis. Arch 
Pathol Lab Med. 2006;130:1466–78.
 8. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, 
et al. PDGFRA activating mutations in gastrointestinal stromal tumors. 
Science. 2003;299:708–10.
 9. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. 
Gain-of-function mutations of platelet-derived growth factor recep-
tor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 
2003;125:660–7.
 10. Liegl B, Kepten I, Le C, Zhu M, Demetri G, Heinrich MC, et al. Hetero-
geneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 
2008;216:64–74.
 11. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, 
et al. KIT kinase mutants show unique mechanisms of drug resistance 
to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc 
Natl Acad Sci USA. 2009;106:1542–747.
 12. Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 
2006;17(Supplement 10):x280–6.
 13. Nannini M, Biasco G, Astolfi A, Pantaleo MA. An overview on molecular 
biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumors 
(GIST). J Med Genet. 2013;50:653–61.
 14. Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foester A, Hartmann 
A, et al. V600E BRAF mutations are alternative early molecular events in 
a subset of KIT/PDGFRA wild-type gastrointestinal tumors. J Clin Pathol. 
2009;62:613–6.
 15. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, et al. 
KRAS and BRAF mutations predict primary resistance to imatinib in 
gastrointestinal stromal tumors. Clin Cancer Res. 2012;18:1769–76.
 16. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, et al. 
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit 
tyrosine kinase. J Biol Chem. 2004;279:31655–63.
 17. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, et al. Dele-
tion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit 
protooncogene is associated with metastatic behavior of gastrointestinal 
stromal tumors. Int J Cancer. 2003;106:887–95.
 18. Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann 
E, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) 
with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 
cases. Mod Pathol. 2008;21:476–84.
 19. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CDM, et al. 
Prognostic value of KIT mutation type, mitotic activity, and histologic sub-
type in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898–905.
 20. Kim TW, Lee H, Kang YK, Choe MS, Ryn MH, Chang HM, et al. Prognostic 
significance of c-kit mutation in localized gastrointestinal stromal tumors. 
Clin Cancer Res. 2004;10:3076–81.
 21. Andersson J, Bumming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joen-
suu H, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions 
are associated with poor prognosis. Gastroenterology. 2006;130:1573–81.
 22. Martin J, Poveda A, Llombart-Bosch A, Ramos R, Lopez-Guerrero JA, 
Garcia del Muro J, et al. Deletions affecting codons 557–558 of the c-KIT 
gene indicate a poor prognosis in patients with completely resected gas-
trointestinal stromal tumors: a study by the Spanish Group for Sarcoma 
Research (GEIS). J Clin Oncol. 2005;23:6190–8.
 23. Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gaumann A, 
et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are com-
mon in adults and frequently show c-KIT mutations. Am J Surg Pathol. 
2007;31:113–20.
 24. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are 
common in incidental gastrointestinal stromal tumors one centimeter or 
less in size. Am J Pathol. 2002;160:1567–72.
 25. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff 
JM, et al. Association of KIT exon 9 mutations with non-gastric primary 
site and aggressive behaviour: KIT mutation analysis and clinical 
correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res. 
2003;9:3329–37.
 26. Lasota J, Kopczynski J, Sarlomo-Rikala M, Schneider-Stock R, Stachura T, 
Kordek R, et al. KIT 1530ins6 mutation defines a subset of predominantly 
malignant gastrointestinal stromal tumors of intestinal origin. Hum 
Pathol. 2003;34:1306–12.
 27. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great major-
ity of GISTs with PDGFRA mutations represent gastric tumors of low or no 
malignant potential. Lab Investig. 2004;84:874–83.
 28. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations 
represent subset of clinically favorable gastric tumors with epithelioid 
morphology. Lab Investig. 2006;86:94–100.
 29. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. 
Progression-free survival in gastrointestinal stromal tumours with high-
dose imatinib: randomised trial. Lancet. 2004;364:1127–34.
 30. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu 
H, et al. Kinase mutations and imatinib response in patients with meta-
static gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.
Page 8 of 8Yan et al. Chin J Cancer  (2016) 35:68 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 31. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, 
van Oosterom AT, et al. KIT mutations and dose selection for imatinib in 
patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 
2006;42:1093–103.
 32. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, 
Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib 
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 
2002;347:472–80.
 33. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, 
et al. Correlation of kinase genotype and clinical outcome in the North 
American Intergroup Phase III Trial of imatinib mesylate for treatment of 
advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer 
and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 
2008;26:5360–7.
 34. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, 
et al. Phase III randomized, intergroup trial assessing imatinib mesylate at 
two dose levels in patients with unresectable or metastatic gastrointes-
tinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J 
Clin Oncol. 2008;26:626–32.
 35. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, 
Fletcher JA, et al. Long-term results from a randomized phase II trial of 
standard- versus higher-dose imatinib mesylate for patients with unre-
sectable or metastatic gastrointestinal stromal tumors expressing KIT. J 
Clin Oncol. 2008;26:620–5.
 36. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, 
Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced 
gastrointestinal stromal tumour after failure of imatinib: a randomised 
controlled trial. Lancet. 2006;368:1329–38.
 37. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. 
Gastrointestinal stromal tumor: role of CT in diagnosis and in response 
evaluation and surveillance after treatment with imatinib. Radiographics. 
2006;26:481–95.
 38. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel 
SR, et al. Correlation of computed tomography and positron emission 
tomography in patients with metastatic gastrointestinal stromal tumor 
treated at a single institution with imatinib mesylate: proposal of new 
computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.
 39. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulat-
ing DNA levels in patients with benign or malignant gastrointestinal 
disease. Cancer. 1983;51:2116–20.
 40. Anker P, Stroun M. Circulating DNA in plasma or serum. Medicina. 
2000;60:699–702.
 41. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 
2002;2:210–9.
 42. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantifica-
tion of free circulating DNA as a diagnostic marker in lung cancer. J Clin 
Oncol. 2003;21:3902–8.
 43. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma 
or serum as biomarker of carcinogenesis: practical aspects and biological 
significance. Mutat Res. 2007;635:105–17.
 44. Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS. Quantification of 
LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann 
N Y Acad Sci. 2008;1137:171–4.
 45. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, 
et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 
2003;63:3966–8.
 46. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumor 
DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis 
Rev. 1999;18:65–73.
 47. Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, et al. Quantification 
of circulating plasma DNA fragments as tumor markers in patients with 
esophageal cancer. Anticancer Res. 2007;27:2737–41.
 48. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. 
Detection of epidermal growth factor receptor mutations in serum as a 
predictor of the response to gefitinib in patients with non-small cell lung 
cancer. Clin Cancer Res. 2006;12:3915–21.
 49. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulat-
ing mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985–90.
 50. Maier J, Lange T, Kerle I, Specht K, Bruegel M, Wickenhauser C, et al. 
Detection of mutant tumor DNA in the plasma of patients with gastroin-
testinal stromal tumor harboring activating mutations in CKIT or PDGFRA. 
Clin Cancer Res. 2013;19(17):4854–67.
 51. Wada N, Kurokawa Y, Takahashi T, Hamakawa T, Hirota S, Naka T, et al. 
Detecting secondary c-KIT mutations in the peripheral blood of patients 
with imatinib-resistant gastrointestinal stromal tumor. Oncology. 
2016;90:112–7.
 52. Powell MJ, Ganta M, Peletskaya E, Pastor L, Raymundo M, Wu G et al. 
High sensitivity detection of tumor gene mutations. BAOJ Cancer Res 
Ther. 2015;1:001. Weblink. http://bioaccent.org/cancer-sciences/cancer-
sciences1.php.
 53. Costa C, Molina MA, Drozdowsky A, Gimenez-Capitan A, Bertran-Alamillo 
J, Karachaliou N, et al. The impact of EGFR T790M mutations and BIM 
mRNA expression on outcome in patients with EGFR-mutant NSCLC 
treated with erlotinib or chemotherapy in the randomized phase III 
EURTAC Trial. Clin Cancer Res. 2014;20(7):1–10.
 54. Gerecke C, Mascher C, Gottschalk U, Kleuser B, Scholtka B. Ultrasensi-
tive detection of unknown colon cancer-initiating mutations using 
the example of the adenomatous Polyposis coli gene. Cancer Prev Res. 
2013;6:898–907.
 55. Myers MB, Banda M, McKim KL, Wang Y, Powell MJ, Parson BL. Breast Can-
cer Heterogeneity examined by high-sensitivity quantitation of PIK3CA, 
KRAS, HRAS, and BRAF mutations in normal breast and ductal carcino-
mas. Neoplasia. 2016;16(4):253–63.
 56. Oktay MH, Adler E, Hakima L, Grunblatt E, Pieri E, Seymour A, et al. The 
application of molecular diagnostics to stained cytology smears. J. Mol. 
Diag. 2016;18(3):407–15.
